164 related articles for article (PubMed ID: 989384)
21. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
Jiang LH; Kasser RJ; Altar CA; Wang RY
J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
[TBL] [Abstract][Full Text] [Related]
22. Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine.
Smith RC; Davis JM
Life Sci; 1976 Sep; 19(5):725-31. PubMed ID: 986527
[No Abstract] [Full Text] [Related]
23. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
24. Effects of haloperidol and low dose clozapine on the acetylcholine turnover rate in rat forebrain structures.
Bluth R; Langnickel R
Biomed Biochim Acta; 1985; 44(10):1531-9. PubMed ID: 4084256
[TBL] [Abstract][Full Text] [Related]
25. Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects.
Sayers AC; Bürki HR; Ruch W; Asper H
Psychopharmacology (Berl); 1976 Dec; 51(1):15-22. PubMed ID: 13446
[TBL] [Abstract][Full Text] [Related]
26. Behavioral and biochemical correlates after haloperidol and clozapine long-term treatment.
Racagni G; Bruno F; Bugatti A; Parenti M; Apud JA; Santini V; Carenzi A; Groppetti A; Cattabeni F
Adv Biochem Psychopharmacol; 1980; 24():45-51. PubMed ID: 7405672
[No Abstract] [Full Text] [Related]
27. [Acute and chronic effects of carpipramine, clozapine, haloperidol and sulpiride on the metabolism of biogenic amines in the rat brain (author's transl)].
von Stralendorff B; Ackenheil M; Zimmermann J
Arzneimittelforschung; 1976; 26(6):1096-8. PubMed ID: 9108
[TBL] [Abstract][Full Text] [Related]
28. The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats.
Imperato A; Angelucci L
Psychopharmacol Bull; 1989; 25(3):383-9. PubMed ID: 2576318
[TBL] [Abstract][Full Text] [Related]
29. Participation of an endogenous Ca++-blinding protein activator in the development of drug-induced supersensitivity of striatal dopamine receptors.
Gnegy M; Uzunov P; Costa E
J Pharmacol Exp Ther; 1977 Sep; 202(3):558-64. PubMed ID: 19618
[No Abstract] [Full Text] [Related]
30. Blockade of central dopaminergic receptors of morphine: effect of haloperidol, apomorphine or benztropine.
Puri SK; Reddy C; Lal H
Res Commun Chem Pathol Pharmacol; 1973 Mar; 5(2):389-401. PubMed ID: 4735501
[No Abstract] [Full Text] [Related]
31. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
32. Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists.
Sethy VH; VAN Woert MH
Res Commun Chem Pathol Pharmacol; 1974 May; 8(1):13-28. PubMed ID: 4847901
[No Abstract] [Full Text] [Related]
33. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
34. Differential nigral expression of Bcl-2 protein family in chronically haloperidol and clozapine-treated rats: role in neurotoxicity and stereotyped behavior.
Saldaña M; Bonastre M; Aguilar E; Marin C
Exp Neurol; 2007 Feb; 203(2):302-8. PubMed ID: 17069804
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacological and neurochemical effects of clozapine (Leponex): new aspects in the drug therapy of schizophrenia].
Bürki HR; Ruch W; Asper H; Baggiolini M; Stille G
Schweiz Med Wochenschr; 1973 Dec; 103(48):1716-24. PubMed ID: 4753069
[No Abstract] [Full Text] [Related]
36. Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency.
Ljungberg T; Ungerstedt U
Psychopharmacology (Berl); 1979 Feb; 60(3):303-7. PubMed ID: 108708
[No Abstract] [Full Text] [Related]
37. [Proceedings: Dopamine receptor and antipsychotic effects (author's transl)].
Karobath M
Arzneimittelforschung; 1976; 26(6):1029-30. PubMed ID: 9103
[No Abstract] [Full Text] [Related]
38. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
39. Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships.
Bürki HR; Sayers AC; Ruch W; Asper H
Arzneimittelforschung; 1977; 27(8):1561-5. PubMed ID: 20900
[TBL] [Abstract][Full Text] [Related]
40. Dopaminergic supersensitivity in striatum and olfactory tubercle following chronic administration of haloperidol or clozapine.
Gianutsos G; Moore KE
Life Sci; 1977 May; 20(9):1585-91. PubMed ID: 875633
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
